In January 2025, the FDA released its first comprehensive AI guidance for drug and biological product development, outlining a risk-based credibility assessment framework that changes how pharma validation teams must approach AI model evaluation. Eight months later, in September 2024, the EMA finalised its Reflection Paper on AI in the medicinal product lifecycle. Then, in January 2026, the FDA and EMA jointly published ten Guiding Principles of Good AI Practice, the first formal co-publication addressing AI across both agencies, spanning every phase of drug development from discovery through post-market surveillance. [1] For pharma AI validation teams that previously operated in a regulatory grey zone, the message from 2025 and 2026 is unambiguous: AI in life sciences has moved from tolerated experiment to formally regulated activity, and model risk evaluation before deployment is no longer optional.
At Pienomial, we built KnolForge as the AI governance platform and trusted AI for high-stakes decisions infrastructure within Knolens specifically because we understood early that pharma organisations deploying AI in regulatory submissions, clinical strategy, and market access decisions cannot do so on a governance framework designed for general enterprise software. The FDA and EMA's converging expectations require a specific, structured model risk evaluation process before any AI system is deployed in a context that touches drug development or regulatory outcomes. This post walks through that process precisely, maps it to the FDA's seven-step credibility framework, and explains how KnolForge's architecture satisfies these requirements by design rather than as a compliance retrofit.[9]
1. Why Model Risk Evaluation in Pharma Is Structurally Different From General Enterprise AI
General enterprise AI risk evaluation frameworks assess technical performance: accuracy, latency, availability, and security. These dimensions matter in pharma too, but they are necessary conditions, not sufficient ones. A pharma AI model risk evaluation must additionally address dimensions that are specific to regulated life sciences contexts: the regulatory consequence of an incorrect output, the patient safety implication of a model error, the GxP data integrity standard that the model's audit trail must satisfy, and the fitness-for-purpose standard that the specific context of use demands.[3]
The EU AI Act, whose requirements for all high-risk AI systems came into force in August 2026, classifies AI used to inform clinical decisions as high-risk, triggering mandatory conformity assessment, transparency documentation, and human oversight obligations across EU member states. [8] The FDA's position is structurally aligned: the January 2025 draft guidance expects drug sponsors to treat AI tools as part of their Quality Management System and to justify their reliability using the same rigour applied to any other validation. An AI model used to support a regulatory submission is not a productivity tool to be evaluated by a procurement team. It is a component of the regulatory quality system, evaluated by a cross-functional validation team applying a structured, documented risk assessment framework.[7]
2. The FDA's Seven-Step Credibility Assessment Framework
The FDA's January 2025 draft guidance introduces a seven-step credibility assessment framework as the central mechanism for evaluating AI models used in regulatory decision-making. The seven steps define a systematic process for establishing that an AI model is fit for its intended purpose in the regulatory context where it will be used.[5]
Step 1, Define the question of interest: What specific decision or analysis will the AI model support? The question of interest must be stated with the specificity required to determine what model performance characteristics matter and which types of error carry the most significant consequences.
Step 2, Identify the context of use (COU): The COU defines the specific role the AI model plays in the regulatory application: what it analyses, what its output represents, how that output will be used by the human decision-maker, and what assumptions underlie its applicability to the specific drug development context. A model's COU is not its general capability. It is the specific, bounded application for which its credibility will be assessed.[6]
Step 3, Identify the model and define the analytical process: Document the model's architecture, training data sources and characteristics, preprocessing steps, output format, and the full analytical workflow from input to decision-relevant output. For AI-as-a-service from external vendors, this step requires specific documentation that vendors must provide and validation teams must independently assess.[4]
Step 4, Characterise risk: Risk in the FDA framework is a function of two dimensions: the influence of the model's output on the regulatory decision and the consequence of an incorrect model output to patient safety or decision quality. A model that directly outputs a safety conclusion carries higher risk than one that provides supporting information that a qualified human evaluates. A model error whose consequence is a missed safety signal carries higher risk than one whose consequence is a delayed analysis. [5] This risk characterisation drives the depth of evidence required in subsequent steps.
Step 5, Plan and execute model credibility activities: The credibility activities are the validation evidence itself: verification that the model performs as specified, validation that it is fit for purpose in its COU, uncertainty quantification, bias assessment, and performance testing on data representative of the intended deployment population. The depth of credibility activities required scales directly with the risk characterisation from Step 4.
Step 6, Document credibility evidence: All credibility activities and their results must be documented in a form that can be submitted as part of the regulatory application or reviewed during a regulatory inspection. Documentation must be traceable, contemporaneous, and structured to allow an independent reviewer to assess the adequacy of the validation evidence without access to the original team.[1]
Step 7, Make and communicate the fitness-for-purpose determination: The culminating step is a human evaluator's documented judgment that the AI model is adequately credible for its defined context of use given the risk characterisation and the credibility evidence assembled. This is not an automated certification. It is a human professional judgment, documented and defensible, that the model meets the standard required for its intended regulatory application.[2]
3. The Five Model Risk Dimensions That Pharma Validation Teams Must Assess
Beyond the seven-step credibility framework, pharma AI validation teams must assess risk across five specific dimensions that are consistently highlighted in FDA, EMA, and EU AI Act guidance as essential components of a robust pre-deployment evaluation.[3]
Dimension 1, Data provenance and representativeness: What data was the model trained on? Is that training data representative of the population and context in which the model will be deployed? For a model being used to analyse clinical trial data from an EU patient population, training data that is predominantly from a different demographic or disease burden context creates a representativeness gap that must be characterised and either addressed or documented as a limitation. The FDA guidance specifically requires characterisation of training data sources, preprocessing steps, and any data selection decisions that could introduce bias.[1]
Dimension 2, Transparency and explainability: Can the model's output be explained in terms that allow a human reviewer to assess its reliability for the specific decision at hand? Opaque black-box models are increasingly untenable for regulatory applications because they cannot satisfy the transparency requirements of NICE, the EU AI Act, or the FDA-EMA joint principles. The validation team must assess whether the model's output includes sufficient methodology documentation for an independent reviewer to evaluate its credibility.[2]
Dimension 3, Bias and fairness assessment: Does the model's performance differ across subgroups relevant to the patient population or clinical context in question? Bias in an AI model used for clinical evidence synthesis or regulatory submission preparation may produce systematically incorrect outputs for specific patient subgroups, exactly the populations whose evidence gaps are most consequential for a NICE or G-BA submission. The validation evidence must include documented bias assessment across relevant subgroups.[8]
Dimension 4, Uncertainty quantification: Every AI model output carries some degree of uncertainty. A robust pre-deployment evaluation quantifies this uncertainty and establishes how the model communicates it to the human reviewer. A model that produces confident-sounding outputs without quantifying the confidence level gives the human reviewer no basis for calibrating how much decision weight to place on the output.[3]
Dimension 5, Lifecycle change management: AI models change over time, whether through deliberate retraining, fine-tuning, or the more subtle changes that occur when a cloud-hosted model's underlying architecture is updated without explicit notification. The validation team must assess what change control mechanisms are in place and whether the model's deployment configuration guarantees the reproducibility of outputs over the regulatory lifecycle of the product it supports.[4]
4. The Vendor Assessment Problem: When the AI Is Someone Else's Model
One of the most pressing practical challenges in pharma AI model risk evaluation is the scenario the FDA specifically flagged for future clarification: AI-as-a-service from external vendors. When a pharma organisation deploys a third-party AI platform for regulatory evidence synthesis, competitive intelligence, or clinical documentation, the model risk evaluation obligation does not transfer to the vendor. The sponsoring organisation remains accountable for demonstrating that the AI system it deployed in its regulatory context satisfies the FDA's credibility framework.[6]
This creates a specific due diligence requirement for vendor assessment before any third-party AI platform is used in a regulated pharma context. The validation team must obtain from the vendor sufficient documentation to complete Steps 3 through 6 of the FDA framework: model architecture and training data documentation, analytical process specification, performance validation evidence for the relevant context of use, uncertainty characterisation methodology, and change control documentation. Vendors that cannot provide this documentation are not suitable for use in regulated pharma applications regardless of their general capability claims.[4]
At Pienomial, we built KnolForge's documentation architecture specifically to satisfy this vendor assessment requirement. Every component of the Knolens platform comes with the technical documentation that a pharma validation team needs to complete its risk assessment: knowledge graph ingestion methodology, extraction validation evidence, inter-rater reliability calculations for screening workflows, audit trail architecture, change control procedures, and the performance evidence required to support a fitness-for-purpose determination for specific regulatory contexts of use.[9]
5. Where Most Pharma AI Deployments Currently Fall Short
A cross-jurisdictional regulatory analysis published in 2026 identified governance frameworks, cybersecurity, and continuous monitoring as the three most consistently underaddressed pillars in current pharma AI validation programmes. [3] These three gaps are not independent: all three reflect the same underlying failure mode, which is treating AI deployment as a one-time validation event rather than a lifecycle management obligation.
The most widespread specific failure is the absence of post-deployment model performance monitoring with defined thresholds. The FDA's guidance requires that performance monitoring be in place for all high-risk AI systems, with defined drift and decay thresholds that trigger formal model review when performance degrades below acceptable bounds, integrated into the organisation's CAPA workflow. Most pharma AI deployments reviewed in independent analyses have no systematic mechanism for detecting performance drift between revalidation cycles. [4] A model that performed adequately at validation may be delivering degraded outputs eighteen months later without any alert mechanism to surface the change.
A second consistent gap is EU AI Act harmonisation. Pharma organisations that have built their AI governance framework around FDA expectations must now map their existing AI inventory against EU AI Act high-risk classifications, identify conformity assessment gaps, and harmonise FDA and EMA documentation requirements into a single unified framework to avoid parallel documentation overhead. [4] For large pharma organisations with dozens of AI systems in active use across regulatory, clinical, and commercial functions, this harmonisation exercise is substantial and time-pressured given the August 2026 compliance deadline for high-risk systems.
6. Building the Pre-Deployment Risk Assessment Package
A structured pre-deployment risk assessment package for a pharma AI system should contain six documented components that together enable both internal validation sign-off and regulatory inspection readiness.[5]
Component 1, Context of use specification: A precise, bounded description of what the AI model will do, in what context, for what decision-maker, and with what downstream regulatory consequence. This specification is the anchor for every subsequent risk evaluation decision.
Component 2, Risk characterisation matrix: A documented assessment of model influence and decision consequence for the defined context of use, producing a risk tier that determines the depth of credibility evidence required. High influence plus high consequence requires the most extensive credibility evidence. Low influence plus low consequence permits a lighter validation approach.
Component 3, Data provenance and representativeness documentation: Source characterisation, preprocessing documentation, bias assessment across relevant subgroups, and representativeness analysis relative to the intended deployment population. For vendor-provided AI systems, this documentation must be obtained from the vendor and verified by the validation team.[1]
Component 4, Performance validation evidence: Accuracy, precision, recall, and uncertainty quantification results from validation testing against data representative of the COU. For LLM-based systems, this includes hallucination rate assessment and citation accuracy testing. For knowledge graph-based retrieval systems, this includes extraction precision and source attribution accuracy.
Component 5, Transparency and explainability assessment: Documentation demonstrating that the model's output generation process is sufficiently transparent to allow a human reviewer to assess its reliability for the specific decision, including whether the model provides source attribution at a level of granularity that satisfies regulatory documentation requirements.
Component 6, Lifecycle management and change control plan: Documented procedures for monitoring model performance post-deployment, defined thresholds that trigger formal review, change control procedures governing model updates and revalidation requirements, and integration of the monitoring alerts into the organisation's CAPA workflow.[4]
7. How KnolForge's Architecture Satisfies the FDA Framework by Design
The most consequential architectural decision in KnolForge's design is that model risk controls are foundational infrastructure rather than a compliance layer added after the fact. This distinction is not cosmetic. It determines whether the risk assessment package a validation team assembles is genuinely defensible or whether it is a documentation exercise that covers a system whose actual architecture does not satisfy the underlying requirements.[9]
On data provenance: the Knolens knowledge graph's validated ingestion pipeline documents every source's verification against independent reference databases before the source's content enters the knowledge layer. The extraction methodology, inter-rater reliability simulation, and source attribution architecture are documented as standard platform outputs, not as retrospective documentation assembled for a specific validation exercise.
On transparency: KnolForge does not use black-box LLM generation as the primary output mechanism for regulated use cases. Every claim in a KnolAI output is retrieved from a sourced entity-relationship triple and linked to its specific primary source at the claim level. A human reviewer can verify any output claim against its source in seconds. This is not a transparency feature. It is the foundational architecture that makes the system appropriate for regulatory use cases at all.[9]
On lifecycle management: KnolForge's change control procedures govern every update to the knowledge layer and inference configuration. Model updates are versioned and documented. Performance monitoring is continuous and built into the platform's operational infrastructure. The performance drift thresholds and CAPA integration that the FDA requires are configured at platform level and apply to every workflow running on KnolForge.[4]
8. Preparing for the FDA's Final AI Guidance in Q2 2026
The FDA signalled in early 2026 that final AI guidance is expected in Q2 2026, incorporating public comment period input and aligning with the January 2026 joint FDA-EMA Guiding Principles. Stakeholders have highlighted specific ambiguities in the draft that the final guidance is expected to clarify: what constitutes sufficient model risk assessment for generative AI and LLMs, how to handle ensemble models with evolving architectures, how to manage AI-as-a-service from external vendors, and whether LLM-based tools require a variant of the seven-step framework.[6]
For pharma validation teams, the right preparation posture is not to wait for final guidance before building the model risk evaluation infrastructure. The seven-step credibility framework in the January 2025 draft, the ten FDA-EMA joint principles from January 2026, and the EU AI Act's high-risk AI requirements all point in the same direction: context of use specificity, data provenance documentation, transparency, human oversight, and lifecycle management. Organisations that have built their AI governance programme around these requirements will find the final guidance clarifying rather than requiring a programme rebuild. Organisations that have deferred governance work pending final guidance will face compressed timelines and elevated risk.[5]
9. How Fast Can Your Validation Team Deploy a Model Risk Framework with KnolForge?
Building the AI governance platform and AI platform life sciences regulatory compliance infrastructure required to satisfy the FDA's seven-step credibility framework does not require a multi-year programme when the underlying AI platform is built to produce the required documentation as a standard operational output. KnolForge is designed to compress this timeline substantially for pharma validation teams.[9]
Sprint 1, Weeks 1 to 2, Risk characterisation and COU specification completed: The validation team works with Pienomial's implementation team to define the context of use for each KnolForge workflow in scope, complete the risk characterisation matrix for each COU, and identify the credibility evidence required for each risk tier. KnolForge's technical documentation package is reviewed and assessed against the FDA framework's Step 3 requirements.
Sprint 2, Weeks 3 to 4, Credibility evidence assembled and validated: Performance validation testing is conducted against the specific contexts of use, with bias assessment across relevant subgroups and uncertainty quantification for each output type. Transparency assessment is completed using KnolForge's claim-level source attribution documentation. The pre-deployment risk assessment package is assembled in the six-component format required for regulatory submission readiness.[3]
Sprint 3, Weeks 5 to 6, Lifecycle management and CAPA integration live: Performance monitoring dashboards are configured with drift and decay thresholds appropriate to each risk tier. CAPA integration is configured so that threshold breaches trigger formal review workflows. Change control procedures are documented and approved. The fitness-for-purpose determination is completed and documented. Your organisation's trusted AI for high-stakes decisions infrastructure is inspection-ready from this sprint forward.[4]
Conclusion
The FDA's seven-step credibility assessment framework, the EMA's transparency and traceability requirements, and the EU AI Act's high-risk classification of clinical AI systems together create a structured, non-negotiable model risk evaluation obligation for every pharma organisation deploying AI in regulated contexts. This is not a compliance burden to be managed. It is a framework that, when implemented correctly, builds the audit trail, the transparency documentation, and the human oversight infrastructure that makes AI outputs genuinely trusted AI for high-stakes decisions rather than productivity tools whose reliability is assumed rather than demonstrated.
At Pienomial, we built KnolForge so that the documentation a validation team needs to complete the FDA's seven-step credibility assessment is a standard output of the platform's operational architecture, not an additional documentation exercise imposed on top of a system that was not designed with regulated deployment in mind. Compliance and capability are not in tension in KnolForge. The architecture that makes the platform compliant is the same architecture that makes it reliable. [9]
CTA: See how KnolForge's governance architecture satisfies the FDA and EMA model risk evaluation requirements. Book a demo with the Pienomial team today
